Antivirals Aid HBeAg-Negative Chronic Hepatitis B Patients

Follow Drugslib on

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

WEDNESDAY, Jan. 3, 2024 -- Continuous nucleos(t)ide analog treatment is effective in lowering the risk for liver cirrhosis in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients, according to a study published in the December issue of the Journal of Clinical and Translational Hepatology.

Jing Zhou, from Sichuan University in Chengdu, China, and colleagues analyzed 194 HBeAg-negative patients with normal alanine transaminase and positive hepatitis B virus (HBV) DNA (≥20 IU/mL) who were untreated, continued treatment, and discontinued treatment (67, 87, and 40 patients, respectively).

The researchers found that during a median follow-up of 54 months, the treatment-continued group achieved 100 percent virological response and significantly reduced aspartate aminotransferase-to-platelet ratio index and fibrosis-4 index scores. Compared with the untreated group, the risk for liver nodules and cirrhosis in the treatment-continued group was reduced. Results were similar compared with the treatment-discontinued group. Among patients with HBV DNA ≥2,000 IU/mL, adherence to treatment lowered the risks for liver cirrhosis compared with both the untreated and the treatment-discontinued groups. Hepatocellular carcinoma was reported by one patient in each of the untreated and treatment-discontinued groups, but not in the treatment-continued group.

"The indications of antiviral therapy should be expanded in that population, especially for those with HBV DNA levels ≥2,000 IU/mL," the authors write. "After treatment is initiated, patient medication compliance needs to be monitored continuously."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-01-04 02:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords